Trek Financial’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$515K Buy
10,744
+2,271
+27% +$97.6K 0.03% 328
2026
Q1
$311K Buy
8,473
+1,565
+23% +$74.2K 0.02% 373
2025
Q4
$351K Buy
6,908
+1,291
+23% +$66K 0.02% 342
2025
Q3
$312K Buy
5,617
+1,340
+31% +$78.4K 0.02% 345
2025
Q2
$295K Buy
+4,277
New +$291K 0.02% 347
2025
Q1
Sell
-2,464
Closed -$212K 428
2024
Q4
$212K Buy
+2,464
New +$266K 0.02% 390
2024
Q3
Sell
-1,840
Closed -$263K 434
2024
Q2
$263K Buy
+1,840
New +$244K 0.02% 325

Other funds holding NVO

Trek Financial's NVO Position: Q2 2026 in Review

Trek Financial increased its Novo Nordisk (NVO) stake by 27% in Q2 2026, buying an estimated $97.6K and bringing the position to 10,744 shares worth $515K. The position accounts for 0.03% of the portfolio, ranked #328.

Trek Financial first reported a position in NVO in Q2 2024 and has held it in 7 quarters since. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Trek Financial held 10,744 shares of Novo Nordisk worth $515K as of Q2 2026.
  • Trek Financial bought 2,271 Novo Nordisk shares in Q2 2026, an estimated $97.6K.
  • Novo Nordisk made up 0.03% of Trek Financial's portfolio in Q2 2026, its #328 holding.
  • Trek Financial first reported a position in Novo Nordisk in Q2 2024 and has held it in 7 quarters since.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Trek Financial's 13F filing for Q2 2026, filed 13 Aug 2026.